• This topic is empty.
Viewing 1 post (of 1 total)
  • Author
    Posts
  • #10413
    admin
    Keymaster

      The development of extracellular vesicle (EV)-based therapies has attracted increasing attention in pharmaceutical research and drug delivery. EVs, including exosomes, have demonstrated interesting potential because of their biocompatibility, biological activity, and ability to transport proteins, nucleic acids, and small-molecule compounds.

      However, one practical challenge remains difficult to ignore: storage stability.

      Many EV preparations are sensitive to storage temperature, formulation conditions, freeze-thaw cycles, and environmental changes. Conventional long-term preservation often relies on ultra-low-temperature storage, which can increase transportation complexity and make large-scale commercialization more difficult.

      This has led researchers to investigate whether lyophilization, or freeze-drying, can provide a more practical approach to EV stabilization. A recent study published in the Journal of Controlled Release has provided interesting evidence that ectoine may serve as a lyoprotectant for milk-derived extracellular vesicles (mEVs).

      Why Is EV Storage Stability So Important?

      Extracellular vesicles are nanoscale membrane-enclosed structures with a lipid bilayer. Their biological functions depend closely on maintaining their physical and biochemical integrity.

      During storage, poorly stabilized EV formulations may experience aggregation, changes in particle size, membrane damage, cargo leakage, or loss of biological activity. These problems can become particularly important when EV technologies move from laboratory research toward pharmaceutical development.

      For long-term preservation, EVs have traditionally been stored at very low temperatures. Although this approach can help maintain EV quality, it also creates practical challenges for transportation, cold-chain management, and distribution.

      For pharmaceutical developers, therefore, an important formulation question is:

      Can EVs be converted into a stable dry formulation without significantly compromising their biological properties?

      Lyophilization is one possible answer.

      What Role Does Lyophilization Play?

      Lyophilization removes water from a formulation under controlled low-temperature and vacuum conditions. It is already widely used for stabilizing various biological products and drug delivery systems.

      For EV formulations, however, freeze-drying is not simply a matter of removing water. The dehydration and freezing steps can potentially affect membrane structure, particle size, molecular interactions, and biological activity.

      This is why the choice of a suitable lyoprotectant is important.

      A good lyoprotectant should help reduce structural damage during freezing and drying while supporting the stability of the resulting dry formulation. Trehalose and other stabilizing excipients have been investigated for biological and vesicular formulations, but researchers continue to explore alternative materials with different mechanisms of stabilization.

      This is where ectoine becomes particularly interesting.

      Why Consider Ectoine as a Lyoprotectant?

      Ectoine is a natural osmoprotectant produced by certain microorganisms to survive harsh environmental conditions such as high salinity, temperature fluctuations, and other forms of stress.

      Its protective properties have made ectoine an interesting material for pharmaceutical and biological applications.

      From a formulation perspective, ectoine can interact with its surrounding hydration environment and help stabilize biological structures. Because extracellular vesicles contain lipid membranes, the ability of ectoine to support membrane and biomolecular stability makes it a candidate worth investigating as a lyoprotective excipient.

      The recent research on milk-derived extracellular vesicles represents an important step in this direction.

      What Did the Recent EV Study Show?

      In July 2025, a research team led by Zhang Ji-wen from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, published the study “Alleviation of dry eye disease with lyophilized extracellular vesicles” in the Journal of Controlled Release.

      The researchers developed an ectoine-enhanced lyophilization strategy for milk-derived extracellular vesicles and evaluated whether ectoine could help preserve their structural and functional properties.

      Several analytical approaches were used, including particle characterization, structural evaluation, β-galactosidase activity measurements, and functional studies.

      The results indicated that ectoine-containing formulations showed improved retention of biological activity after lyophilization. In particular, the study reported that 1.5% ectoine helped maintain stable energy-transfer efficiency in DiO/DiI co-labeled mEVs.

      The findings suggest that ectoine may help protect EV structures during the freeze-drying process rather than simply acting as an inert formulation component.

      Storage Stability at 4°C

      One of the most interesting aspects of the research was the storage evaluation.

      Untreated mEVs showed noticeable changes after 60 days of storage at 4°C, including increased particle size and reduced particle count.

      In comparison, the lyophilized mEV formulations showed much smaller changes in particle size and particle count under the same storage conditions.

      For EV developers, this result is particularly relevant.

      If a dry formulation can maintain the critical properties of EVs under refrigerated conditions for an extended period, it could potentially simplify certain aspects of storage and transportation compared with conventional ultra-low-temperature approaches.

      Of course, further formulation optimization, stability studies, analytical characterization, and regulatory evaluation would still be necessary before such approaches could be broadly applied to commercial pharmaceutical products.

      Potential Application in Dry Eye Disease

      The study did not stop at formulation stability. Researchers also investigated the biological performance of the lyophilized mEVs.

      In vitro experiments showed that lyophilized mEVs could protect human corneal epithelial cells from damage associated with hyperosmotic conditions.

      The researchers also evaluated the formulation in a benzalkonium chloride-induced dry eye disease model using New Zealand rabbits.

      The lyophilized mEV group showed a lower corneal staining score than the model and ectoine-only groups, suggesting improved corneal epithelial repair. The study also reported improved tear secretion in the treatment group.

      These findings are scientifically interesting because they connect formulation stabilization with biological performance.

      In other words, the objective of using a lyoprotectant is not simply to produce a convenient powder. The ultimate goal is to preserve the functional characteristics of the biological payload.

      What Does This Mean for Exosome Formulation Development?

      Exosomes are a subtype of extracellular vesicles and have attracted considerable interest in drug delivery research.

      Their natural membrane structure and biological characteristics make them potential carriers for different types of therapeutic cargo. However, formulation and storage remain important challenges for the development of exosome-based products.

      The ectoine study focused on milk-derived EVs rather than establishing a universal exosome formulation platform. Therefore, the results should not be interpreted as proof that every exosome formulation will behave identically.

      Nevertheless, the research provides a useful direction for formulation scientists:

      Ectoine may be worth investigating as a lyoprotectant in future EV and exosome formulation development.

      The potential advantages include improved structural stability during lyophilization, better preservation of biological properties, and the possibility of developing more practical storage conditions.

      Why Excipient Selection Matters in Advanced Drug Delivery

      As pharmaceutical delivery systems become more sophisticated, excipients are increasingly important components of formulation design.

      For traditional small-molecule formulations, excipient selection may focus on solubility, stability, viscosity, release characteristics, or bioavailability.

      For biological and nanostructured delivery systems, the formulation challenge can be considerably more complex.

      The excipient may need to protect:

      • Particle size distribution

      • Membrane integrity

      • Protein structure

      • Nucleic acid stability

      • Biological activity

      • Interfacial stability

      • Long-term storage performance

      This is particularly relevant for EVs, liposomes, lipid nanoparticles, and other advanced delivery platforms.

      Consequently, pharmaceutical developers need to evaluate excipients not only according to their basic chemical properties but also according to their compatibility with the specific delivery system.

      Ectoine and the Future of Biological Formulations

      The growing interest in ectoine is not limited to EV stabilization.

      Ectoine has already attracted attention in ophthalmic and mucosal applications because of its protective and moisturizing properties. It has been used in certain eye-care products and has also been investigated for applications such as nasal and throat formulations.

      Its combination of biological protection and formulation potential makes ectoine an interesting candidate for further research in pharmaceutical excipients.

      For companies developing advanced drug delivery systems, several questions may be worth exploring:

      • What concentration of ectoine provides optimal protection?

      • How does ectoine compare with trehalose and other lyoprotectants?

      • How does ectoine affect different EV sources?

      • Can ectoine improve long-term storage under refrigerated conditions?

      • How does the excipient affect reconstitution after lyophilization?

      • Does the formulation maintain biological activity after extended storage?

      • What quality and regulatory requirements should be considered for pharmaceutical-grade ectoine?

      These questions will require systematic formulation development and analytical validation.

      Conclusion

      The stability of extracellular vesicles remains an important challenge in the development of EV- and exosome-based therapeutics. Lyophilization offers a potentially valuable strategy, but the success of the process depends heavily on formulation design and the selection of suitable protective excipients.

      Recent research has demonstrated that ectoine can help preserve the structural and functional properties of milk-derived extracellular vesicles during lyophilization, with lyophilized mEVs showing improved stability during refrigerated storage and promising activity in dry eye disease models.

      Although additional research is needed before ectoine-based EV formulations can be considered a broadly established pharmaceutical solution, the findings provide an interesting direction for researchers working on extracellular vesicles, exosomes, lyophilized formulations, ophthalmic drug delivery, and biological excipients.

      For formulation development teams, ectoine may therefore deserve closer attention—not only as a potential protective agent for EVs, but also as part of the broader search for more stable and practical advanced drug delivery systems.

      https://www.avt-pharma.com/about.html
      AVT Pharmaceutical

    Viewing 1 post (of 1 total)
    • You must be logged in to reply to this topic.